Literature DB >> 28987427

Deep Venous Thrombosis.

Mark Olaf1, Robert Cooney2.   

Abstract

Deep venous thrombosis (DVT) is a frequently encountered condition that is often diagnosed and treated in the outpatient setting. Risk stratification is helpful and recommended in the evaluation of DVT. An evidence-based diagnostic approach is discussed here. Once diagnosed, the mainstay of DVT treatment is anticoagulation. The specific type and duration of anticoagulation depend upon the suspected etiology of the venous thromboembolism, as well as risks of bleeding and other patient comorbidities. Both specific details and a standardized approach to this vast treatment landscape are presented.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Deep venous thrombosis; Novel oral anticoagulant; Venous thromboembolism; Vitamin K antagonist

Mesh:

Year:  2017        PMID: 28987427     DOI: 10.1016/j.emc.2017.06.003

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  16 in total

1.  Risk Prediction and Treatment of LE-DVT in Patients with Chronic Radiation Intestinal Injury: A Retrospective Case-Control Study.

Authors:  Xiaoyan Huang; Yingyi Kuang; Qiyuan Qin; Hui Wang; Tenghui Ma; Xinjuan Fan; Miaomiao Zhu; Yanjiong He; Zixu Yuan; Huaiming Wang; Qinghua Zhong; Qi Guan
Journal:  Cancer Manag Res       Date:  2021-08-23       Impact factor: 3.989

2.  NLR value and IL-18 level and their clinical significance in patients with deep vein thrombosis after receiving the surgery for spinal degeneration.

Authors:  Yukun Zhang; Mingyu Cao; Jun Ren
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Hypereosinophilia with Concurrent Venous Thromboembolism: Clinical Features, Potential Risk Factors, and Short-term Outcomes in a Chinese Cohort.

Authors:  Yecheng Liu; Xu Meng; Jun Feng; Xianliang Zhou; Huadong Zhu
Journal:  Sci Rep       Date:  2020-05-20       Impact factor: 4.379

4.  Elevated miR-195-5p expression in deep vein thrombosis and mechanism of action in the regulation of vascular endothelial cell physiology.

Authors:  Jinlong Jin; Caixia Wang; Yujuan Ouyang; Dandan Zhang
Journal:  Exp Ther Med       Date:  2019-11-04       Impact factor: 2.447

Review 5.  Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.

Authors:  Muhammad Ajmal; Jacob Friedman; Qurat Ul Ain Riaz Sipra; Tom Lassar
Journal:  Cardiovasc Ther       Date:  2021-01-08       Impact factor: 3.023

6.  Peripherally inserted central venous catheter in upper extremities leads to an increase in D-dimer and deep vein thrombosis in lower extremities.

Authors:  Wanli Liu; Lianxiang He; Wenjing Zeng; Liqing Yue; Jie Wei; Shuangshuang Zeng; Xiang Wang; Zhicheng Gong
Journal:  Thromb J       Date:  2021-04-09

Review 7.  Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review.

Authors:  Duo Lan; Siying Song; Yunhuan Liu; Baolian Jiao; Ran Meng
Journal:  Front Neurol       Date:  2021-12-02       Impact factor: 4.003

8.  Phlegmasia cerulea dolens in a patient treated with carboplatin.

Authors:  Martin Söderman; Peter Grimm
Journal:  BMJ Case Rep       Date:  2020-04-14

9.  Down-regulation of miR-361-5p promotes the viability, migration and tube formation of endothelial progenitor cells via targeting FGF1.

Authors:  Xiaofeng Yang; Yanli Song; Yuexi Sun; Mengmeng Wang; Yang Xiang
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

10.  Pulmonary thromboembolism and alveolar hemorrhage as initial manifestations of systemic lupus erythematosus.

Authors:  O Jiménez-Zarazúa; L N Vélez-Ramírez; C A Ramírez-Casillas; J D Mondragón
Journal:  Lupus       Date:  2022-01-18       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.